https://ldl-receptor.com/index.....php/the-result-of-y
Utilizing D-dimer values from people enrolled to your AVERT trial, we sought to identify and verify an even more efficient venous thromboembolism (VTE) threat limit for thromboprophylaxis. Five hundred seventy-four patients had been randomized when you look at the AVERT trial; 466 (81%) with standard D-dimer had been within the study. Two hundred thirty-seven subjects received apixaban; 229 got placebo. When you look at the full cohort, there have been 13
Like
Comment
Share
